GenProb‐PCSM: A Simplified Weighted Germline Score for Prostate Cancer‐Specific Mortality
The Prostate · 2026-12 · 86 (16) · 1604-1611
DOI: 10.1002/pros.70244 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, online erschienen am 08.09.2026. Verfasst von Jun Wei und 14 weiteren Autor:innen. Beteiligte Einrichtung: Program for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Germ-Line Mutation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
We previously developed a tier‐based germline classification using the National Comprehensive Cancer Network (NCCN)‐recommended DNA damage repair (DDR) genes and KLK3 I179T to predict prostate cancer (PCa)‐specific mortality (PCSM). To provide an easier‐to‐use single inherited risk score while preserving gene‐specific effects, we developed GenProb‐PCSM.
Methods
We analyzed 14,644 men with incident PCa from the UK Biobank. The cohort was randomly divided into training (60%) and independent testing (40%) datasets. GenProb‐PCSM was developed in the training cohort by integrating pathogenic variants in ten NCCN‐recommended DDR genes and the KLK3 I179T variant using gene‐specific weights derived from Fine–Gray competing‐risk models. Performance was evaluated in the independent testing cohort by discrimination, calibration, and risk stratification. Secondary analyzes evaluated metastatic progression and the composite endpoint of metastatic progression and/or PCSM.
Results
Among 14,644 men with incident PCa, 1,581 died from PCa. GenProb‐PCSM remained significantly associated with PCSM in the independent testing cohort (HR per SD, 1.18; 95% CI, 1.12–1.24; p < 0.001). Using predefined risk thresholds derived from the training cohort, patients in the intermediate‐ and high‐risk groups had significantly increased risks of PCSM compared with the low‐risk group (HR 1.49, 95% CI 1.22–1.84; and HR 4.04, 95% CI 2.58–6.33, respectively). GenProb‐PCSM also predicted independent metastatic progression and the composite endpoint of metastatic progression and/or PCSM.
Conclusions
GenProb‐PCSM transforms complex germline findings into a single inherited risk score for PCSM and metastatic progression. Its simplicity and preservation of gene‐specific effects may facilitate clinical implementation of germline prognostic assessment in PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA.
- GoPath Diagnostics, Buffalo Grove, Illinois, USA.
- Genomic Health Initiative, Endeavor Health, Evanston, Illinois, USA.
- University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.
- James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- Division of Urology, Endeavor Health, Evanston, Illinois, USA.
ORCID-Profile: Jun Wei, Ashley J Mulford, Alan R Sanders, Brian Helfand, Jianfeng Xu
Zitieren
APA
Wei, J., Shi, Z., Lu, L., Wang, J., Xu, J., Mulford, A. J., Tran, H., Ashworth, A., Lilly Zheng, S., Sanders, A. R., Issacs, W. B., Luo, J., Helfand, B., Lu, J., & Xu, J. (2026). GenProb‐PCSM: A Simplified Weighted Germline Score for Prostate Cancer‐Specific Mortality. The Prostate, 86(16), 1604-1611. https://doi.org/10.1002/pros.70244
Vancouver
Wei J, Shi Z, Lu L, Wang J, Xu J, Mulford AJ, et al. GenProb‐PCSM: A Simplified Weighted Germline Score for Prostate Cancer‐Specific Mortality. The Prostate. 2026;86(16):1604-1611. doi:10.1002/pros.70244
BibTeX
@article{Wei2026,
author = {Wei, Jun and Shi, Zhuqing and Lu, Lucy and Wang, John and Xu, Julian and Mulford, Ashley J and Tran, Huy and Ashworth, Annabelle and Lilly Zheng, S and Sanders, Alan R and Issacs, William B and Luo, Jun and Helfand, Brian and Lu, Jim and Xu, Jianfeng},
title = {GenProb‐PCSM: A Simplified Weighted Germline Score for Prostate Cancer‐Specific Mortality},
journal = {The Prostate},
year = {2026},
volume = {86},
number = {16},
pages = {1604--1611},
doi = {10.1002/pros.70244}
}
EUVIMED